CYP19A1 and cancer: Epigenetic changes in different classes of this type of cancer have been studied, including: estrogen receptor positive (ER+), that are estrogen-level dependent; estrogen receptor negative (ER-), whose tumor cells are not responsive to estrogen thus resistant to antiestrogenic drugs such as tamoxifen and aromatase inhibitors; progesterone receptor (PR); and human epidermal growth factor 2 (HER2)-related cancers [49,51-58].